Neosh101

Neosh101

Neosh101 at a glance

Rating: 2.7/5 (10 votes cast)

The good: Promising trial results

The bad: Only shows 4% regrowth so far, and is yet another treatment wallowing in trial phases.

Bottom Line: Keep an eye on this one, it will likely outperform Rogaine. Just don't hold your breath for it to reach market soon.

Help improve this page

Neosh101 (tetrapeptide aldehyde proteasome inhibitor) is a commercially marketed antiinflammatory and growth stimulant. It is applied topically.

Neosh101 is said to inhibit proteasomal and NF-.kappa.B activity. This is claimed to reduce inflammation and stimulate the production of hair follicles, which in turn stimulates hair growth and density.

Neosh101 is marked and developed by Neosil, Inc., a privately held dermatology-focused pharmaceutical company. Neosil seems to be aligning Neosh101 against Rogaine, which is still the gold standard in topical hairloss combatants.

Neosh101 is currently in Phase IIb trials[1]. With this in mind, it's reasonable to expect that as a best case, 2009 would be the first commercial release date.

Phase IIa results were positive with once-daily topical treatments[2]:

  1. Increase in total hair count and cumulative hair thickness.
  2. Superior results to Rogaine in the same models.
  3. Enhanced hair re-growth in a chemotherapy-induced alopecia model.
  4. Non-GLP pre-clinical toxicity studies showed complete safety.

Contents

[edit] Timeline

Feb 2008 - Trial results expected

Jan 2007 - Neosil announces positive phase IIa results. Growth was "increased significantly in men with androgenetic alopecia / pattern hair loss".

Feb 2005 - Neosil buys rights to Neosh101 from OSTEOSCREEN. [3]

[edit] Side Effects

Unknown at this time, but there is some evidence that completely suppressing NF-.kappa.B would be detrimental to hair. [4]

[edit] See also

[edit] References

  1. ↑ Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
  2. ↑ NEOSIL ANNOUNCES POSITIVE PHASE 2 DATA FOR NEOSH101, AN INVESTIGATIONAL TREATMENT FOR ANDROGENETIC ALOPECIA
  3. ↑ NEOSIL ACQUIRES TOPICAL PRODUCTS FROM OSTEOSCREEN
  4. ↑ Requirement of NF-kappaB/Rel for the development of hair follicles and other epidermal appendices.
Retrieved from "http://tressless.com/wiki/Neosh101"

User Comments


    Add comment